Although combined oral contraceptives (COCs) are a safe and highly effective method of birth control, they may also give rise to problems of clinical tolerability in migraine patients. Indeed, headache is among the most common side effects reported with the use of COCs, frequently leading to their being discontinued. The latest International Classification of Headache Disorders identified at least two entities evidently related to the use of COCs, i.e., exogenous hormone-induced headache and estrogen-withdrawal headache. As to the former, the newest formulations of COCs are generally well tolerated by migraine without aura patients, but can worsen headache in migraine with aura patients. Headache associated with COCs, generally, tends to improve as their use continues. However, although it is not yet clear if there is an association between headache and the composition of COCs (both in the type and amount of hormones), it has been observed that the incidence of headache during COC use seems greater if migraine is associated with menstrual trigger. The estrogen-withdrawal headache is a headache that generally appears within the first 5 days after cessation of estrogen use and resolves within 3 days, even if in some cases it may appear on the sixth or seventh day after pill suspension and lasts more than 3 days.
This is a preview of subscription content, log in to check access.
Conflict of interest statement
The authors declare that they have no conflict of interest related to the publication of this manuscript.
Loder EW, Buse DC, Golub JR (2005) Headache as a side effect of combination estrogen–progestin oral contraceptives: a systematic review. Am J Obstet Gynecol 193:636–649PubMedCrossRefGoogle Scholar
Headache Classification Subcommittee of the International Headache Society (IHS) (2004) The International Classification of Headache Disorders (2nd edition). Cephalalgia 24(Suppl 1):1–151Google Scholar
Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Nappi G (2000) Migraine with aura and reproductive life events: a case control study. Cephalalgia 20(8):701–707PubMedCrossRefGoogle Scholar
MacGregor EA, Igarashi H, Wilkinson M (1997) Headaches and hormones: subjective versus objective assessment. Headache Q 8:126–136Google Scholar
Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M (1995) Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 15:140–144PubMedCrossRefGoogle Scholar
Granella F, Sances G, Zanferrari C, Costa A, Martignoni GC (1993) Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 33:385–389PubMedCrossRefGoogle Scholar
Massiou H, MacGregor EA (2000) Evolution and treatment of migraine with oral contraceptives. Cephalalgia 20:170–174PubMedCrossRefGoogle Scholar
Fotherby K (1992) Clinical experience and pharmacological effects of an oral contraceptive containing 20 micrograms oestrogen. Contraception 46:477–488PubMedCrossRefGoogle Scholar
Allais G, Bussone G, Airola G, Borgogno P, Castagnoli Gabellari I, De Lorenzo C et al (2008) Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. Neurol Sci 29(Suppl 1):S186–S190PubMedCrossRefGoogle Scholar